Method for expecting and diagnosing uqcrb-related disease

Abstract

Disclosed is a method for expecting and diagnosing UQCRB-related disease, and more particularly, related to a method for diagnosing a UQCRB-related disease and a cholesterol biosynthesis related disease, as well as expecting risks of post-occurrence of the UQCRB-related disease and the cholesterol biosynthesis related disease, simply by measuring an expression level of miRNA, and a kit and a biomarker composition for the method.

What is claimed is: 
     
         1 . A method for expecting and diagnosing a UQCRB-related disease, the method comprising:
 measuring an expression level of at least one miRNA, which is selected from a group formed of hsa-miR-1323, hsa-miR-512-3p, and hsa-miR-10a-5p, in a sample;   comparing a pattern of the measured expression level(s) with one of expression levels or several reference patterns; and   diagnosing or expecting the UQCRB-related disease from the compared result of the sample and the reference patterns.   
     
     
         2 . The method of  claim 1 , wherein the sample is selected from a group formed of a blood sample, a serum sample, a plasma sample, a urine sample, and sputum. 
     
     
         3 . The method of  claim 1 , wherein the measuring of the expression level comprises: measuring an expression level of hsa-miR-1323. 
     
     
         4 . The method of  claim 1 , wherein the measuring of the expression level comprises: measuring an expression level of hsa-miR-512-3p. 
     
     
         5 . The method of  claim 1 , wherein the measuring of the expression level comprises: measuring an expression level of hsa-miR-10a-5p. 
     
     
         6 . The method of  claim 1 , wherein the measuring of the expression level comprises: selecting one from a group formed of reverse transcriptase polymerase chain reaction, real time polymerase chain reaction, Western blot, Northern blot, enzyme linked immunosorbent assay (ELISA), radioimmunoassay (RIA), radioimmunodiffusion, and immunoprecipitation assay. 
     
     
         7 . The method of  claim 1 , wherein the UQCRB-related disease is related to cholesterol synthesis. 
     
     
         8 . The method of  claim 1 , wherein the UQCRB-related disease arises from an increase of expression of cholesterol synthetase due to over-expression of UQCRB. 
     
     
         9 . The method of  claim 8 , wherein the cholesterol synthetase is HMG-CoA reductase (HMGCR), pyrophophosmevalnote decarboxylase (MVD), or lanosterol synthase (LSS). 
     
     
         10 . A biomarker composition for expecting or diagnosing UQCRB-related disease, comprising:
 an agent detecting at least one miRNA selected from a group formed of hsa-miR-1323, hsa-miR-512-3p, and hsa-miR-10a-5p.   
     
     
         11 . The biomarker composition of  claim 10 , wherein the agent is a probe or primer having a sequence complementary to a nucleotide sequence of at least one miRNA selected from a group formed of hsa-miR-1323, hsa-miR-512-3p, and hsa-miR-10a-5p. 
     
     
         12 . A kit for expecting and diagnosing a UQCRB-related disease, comprising:
 means configured to measure an expression level of at least one miRNA selected from a group, which is formed of hsa-miR-1323, hsa-miR-512-3p, and hsa-miR-10a-5p, in a sample; and   at least one reference pattern including an expression level that is to be compared with the measured expression level of the miRNA that is taken from the sample.   
     
     
         13 . The kit of  claim 12 , further comprising: a primer complementary to at least one miRNA selected from a group formed of hsa-miR-1323, hsa-miR-512-3p, and hsa-miR-10a-5p and configured to amplify the miRNA. 
     
     
         14 . The kit of  claim 12 , further comprising: an antibody, antisense oligonucleotide, or probe for at least one miRNA selected from a group formed of hsa-miR-1323, hsa-miR-512-3p, and hsa-miR-10a-5p.